{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T12:08:46Z","timestamp":1779797326843,"version":"3.53.1"},"reference-count":21,"publisher":"Scientific Scholar","content-domain":{"domain":["ijmr.org.in"],"crossmark-restriction":true},"short-container-title":["Indian J Med Res"],"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>\n                      Lifestyle interventions are a vital component for the management of metabolic dysfunction-associated steatotic liver disease (MASLD). In the present study, we investigated the differential effect of saroglitazar or vitamin E\n                      <jats:italic>vs.<\/jats:italic>\n                      lifestyle interventions only.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total 150 non-diabetic patients aged 19-55 yr were recruited to receive saroglitazar and vitamin E along with lifestyle interventions and lifestyle interventions alone (n=50 in each arm, A, B and C, respectively) for 24 weeks. Liver stiffness measurements and NAFLD fibrosis score were the primary outcomes. The study was registered under Trial registration (CTRI\/2022\/05\/042462).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Per-protocol analysis was performed in 136 patients (n=46, 47, and 43 in arms A, B and C, respectively). The changes from baseline were not-significant for NAFLD fibrosis score [0.05\u00b10.52, 0.06\u00b10.64 and -0.12\u00b11.0, 95% confidence interval (CI),\n                      <jats:italic>P<\/jats:italic>\n                      =0.41] and liver stiffness measurement [-1.25 (-2.6, -0.2), -1.4 (-3.7, 0.4,) and -0.7 (-1.8, -0.2),\n                      <jats:italic>P<\/jats:italic>\n                      =0.22] in either arm. Changes in secondary outcomes were also not-significant except triglyceride [-13.95 (-61, -18), -4.3 (-28.8, 49) and -13 (-127, 3)\n                      <jats:italic>P<\/jats:italic>\n                      =0.035]. A considerable proportion of patients had at least \u20182 Kpa reduction\u2019 in liver stiffness measurement in arm A (39%) compared to C (19%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation and conclusions<\/jats:title>\n                    <jats:p>Saroglitazar or vitamin E are similar to lifestyle interventions in improving different non-invasive parameters in MASLD at 24 weeks of intervention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.25259\/ijmr_2511_2025","type":"journal-article","created":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T12:14:30Z","timestamp":1779020070000},"page":"598-605","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Saroglitazar and vitamin E\n                    <i>vs<\/i>\n                    . lifestyle interventions in metabolic dysfunction associated steatotic liver disease: A 3-arm randomised study"],"prefix":"10.25259","volume":"163","author":[{"given":"Anurag Kumar","family":"Tiwari","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurvachan","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawesh Prakash","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunit Kumar","family":"Shukla","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virendra","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra Kumar","family":"Tiwary","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, RG Kar Medical College and Hospital, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Anunay","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divyanshi","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Chaturvedi","sequence":"additional","affiliation":[{"name":"Department of Medical Health and Family Welfare, PDDU Hospital, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"key":"10.25259\/IJMR_2511_2025\/ref-1","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol."},{"key":"10.25259\/IJMR_2511_2025\/ref-2","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin Mol Hepatol."},{"key":"10.25259\/IJMR_2511_2025\/ref-3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/cld.1141","article-title":"Nonalcoholic fatty liver disease: Indian perspective","volume":"18","author":"De","year":"2021","journal-title":"Clin Liver Dis (Hoboken)."},{"key":"10.25259\/IJMR_2511_2025\/ref-4","first-page":"310","article-title":"A community-based study to determine the prevalence of nonalcoholic fatty liver disease (NAFLD) and its metabolic risk factors in urban and rural communities of North India","volume":"34","author":"Mahajan","year":"2019","journal-title":"J\u00a0Gastroenterol Hepatol."},{"key":"10.25259\/IJMR_2511_2025\/ref-5","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.3390\/ijms25084397","article-title":"The relationship between pathogenesis and possible treatments for the MASLD-cirrhosis spectrum","volume":"25","author":"Vidal-Cevallos","year":"2024","journal-title":"Int J Mol Sci."},{"key":"10.25259\/IJMR_2511_2025\/ref-6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.14744\/hf.2021.2021.0014","article-title":"Sustainability of diet-based moderate calorie restriction among obese patients with metabolic-associated fatty liver disease","volume":"2","author":"Guveli","year":"2021","journal-title":"Hepatol Forum."},{"key":"10.25259\/IJMR_2511_2025\/ref-7","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.3390\/antiox12071318","article-title":"Adherence to mediterranean diet: Any association with NAFLD?","volume":"12","author":"Barrea","year":"2023","journal-title":"Antioxidants (Basel)"},{"key":"10.25259\/IJMR_2511_2025\/ref-8","doi-asserted-by":"publisher","first-page":"1225946","DOI":"10.3389\/fnut.2023.1225946","article-title":"Mediterranean diet affects the metabolic outcome of metabolic dysfunction-associated fatty liver disease","volume":"10","author":"Xiao","year":"2023","journal-title":"Front Nutr."},{"key":"10.25259\/IJMR_2511_2025\/ref-9","doi-asserted-by":"publisher","first-page":"1439473","DOI":"10.3389\/fnut.2024.1439473","article-title":"Effect of 5:2 intermittent fasting diet versus daily calorie restriction eating on metabolic-associated fatty liver disease-a randomized controlled trial","volume":"11","author":"Wang","year":"2024","journal-title":"Front Nutr."},{"key":"10.25259\/IJMR_2511_2025\/ref-10","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: First approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs."},{"key":"10.25259\/IJMR_2511_2025\/ref-12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12933-020-01073-w","article-title":"Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: A 56-week, randomized, double blind, phase 3 study (PRESS XII study)","volume":"19","author":"Krishnappa","year":"2020","journal-title":"Cardiovasc Diabetol."},{"key":"10.25259\/IJMR_2511_2025\/ref-13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12933-019-0884-3","article-title":"New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: Integrated analysis of the real world evidence","volume":"18","author":"Kaul","year":"2019","journal-title":"Cardiovasc Diabetol."},{"key":"10.25259\/IJMR_2511_2025\/ref-14","doi-asserted-by":"publisher","first-page":"21117","DOI":"10.1038\/s41598-020-78342-x","article-title":"Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: A prospective, observational, real world study","volume":"10","author":"Goyal","year":"2020","journal-title":"Sci Rep."},{"key":"10.25259\/IJMR_2511_2025\/ref-15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jceh.2022.11.014","article-title":"Indian national association for study of the liver (INASL) guidance paper on nomenclature, diagnosis and treatment of nonalcoholic fatty liver disease (NAFLD)","volume":"13","author":"Duseja","year":"2023","journal-title":"J Clin Exp Hepatol."},{"key":"10.25259\/IJMR_2511_2025\/ref-16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/jgh3.12878","article-title":"Efficacy and safety of saroglitazar in real-world patients of non-alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience","volume":"7","author":"Chaudhuri","year":"2023","journal-title":"JGH Open."},{"key":"10.25259\/IJMR_2511_2025\/ref-17","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin e, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med."},{"key":"10.25259\/IJMR_2511_2025\/ref-18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/apt.12352","article-title":"Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis","volume":"38","author":"Hoofnagle","year":"2013","journal-title":"Aliment Pharmacol Ther."},{"key":"10.25259\/IJMR_2511_2025\/ref-19","doi-asserted-by":"publisher","first-page":"101398","DOI":"10.1016\/j.jceh.2024.101398","article-title":"A prospective randomised comparative four-arm intervention study of efficacy and safety of saroglitazar and vitamin E in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)\/non-alcoholic steatohepatitis (NASH)-SVIN TRIAL","volume":"14","author":"Mir","year":"2024","journal-title":"J Clin Exp Hepatol."},{"key":"10.25259\/IJMR_2511_2025\/ref-20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology."},{"key":"10.25259\/IJMR_2511_2025\/ref-21","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1007\/s10620-014-3380-3","article-title":"Total body weight loss of = 10% is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis","volume":"60","author":"Glass","year":"2015","journal-title":"Dig Dis Sci."},{"key":"10.25259\/IJMR_2511_2025\/ref-22","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1517\/14656566.2015.1009894","article-title":"Saroglitazar for the treatment of dyslipidemia in diabetic patients","volume":"16","author":"Joshi","year":"2015","journal-title":"Expert Opin Pharmacother."}],"container-title":["The Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ijmr.org.in\/saroglitazar-and-vitamin-e-vs-lifestyle-interventions-in-metabolic-dysfunction-associated-steatotic-liver-disease-a-3-arm-randomised-study\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/ijmr.org.in\/saroglitazar-and-vitamin-e-vs-lifestyle-interventions-in-metabolic-dysfunction-associated-steatotic-liver-disease-a-3-arm-randomised-study\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:54:21Z","timestamp":1779796461000},"score":1,"resource":{"primary":{"URL":"http:\/\/ijmr.org.in\/saroglitazar-and-vitamin-e-vs-lifestyle-interventions-in-metabolic-dysfunction-associated-steatotic-liver-disease-a-3-arm-randomised-study\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":21,"alternative-id":["10.25259\/IJMR_2511_2025"],"URL":"https:\/\/doi.org\/10.25259\/ijmr_2511_2025","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"article-number":"598"}}